• Revenue up 55.6% to $393.5m
• EBITDA up 91.4% to $67.1m
• EBIT up 161.8% to $30.2m
• Profit after tax up to $9.0m

Integral Diagnostics Limited reported its financial results for the half year ended 31 December 2025. Revenue was up 55.6% to $393.5 million, driven by the acquisition of Capitol Health in the prior year, as well as organic growth in patient volumes, Medicare indexation, and favorable mix impacts. EBITDA increased 91.4% to $67.1 million, and EBIT rose 161.8% to $30.2 million. Profit after tax attributable to the owners of Integral Diagnostics Limited was $9.0 million, up from a loss in the prior comparative period. The company's operating results reflect solid revenue growth, Medicare indexation, and strong performance from both the legacy IDX and Capitol businesses. The Capitol merger integration is proceeding on plan, with synergies significantly exceeding initial expectations. The company's net debt/EBITDA ratio improved to 2.5x, and it remains in compliance with all debt facility covenants. Integral Diagnostics' focus for FY26 and beyond will be on driving organic earnings growth, accelerating the use of teleradiology and digital/AI technologies, and completing the IDX-Capitol integration while evaluating further M&A opportunities.

The company expects to achieve annual ongoing synergies of $14.0m+ from the Capitol Health merger, up from the initial expectation of at least $10.0m.

Integral Diagnostics' key focus areas for FY26 and beyond include driving organic earnings growth, accelerating the use of teleradiology and digital/AI technologies, executing the company's ESG strategy, and completing the IDX-Capitol integration while evaluating further M&A opportunities in the consolidating market.